Clinical Scorecard: Transitioning from relapse to survival: the clinical effectiveness of a multimodal strategy in patients with first-time recurrent glioblastoma
At a Glance
Category
Detail
Condition
Glioblastoma (GBM)
Key Mechanisms
Multimodal strategy integrating surgical resection, radiotherapy, and temozolomide (TMZ) treatment.
Target Population
Adults with first-time recurrent glioblastoma, age > 18.
Care Setting
Multidisciplinary oncology team management.
Key Highlights
GBM is the most prevalent malignant brain tumor in adults, typically diagnosed after age 65.
Tumor recurrence occurs in approximately 75% of patients within one year of diagnosis.
Median overall survival after recurrence is under 2 years.
Multimodal treatment strategies show improved overall survival compared to singular approaches.
Bevacizumab and alternative chemotherapeutics are commonly used in recurrent cases.
Guideline-Based Recommendations
Diagnosis
Histologically verified diagnosis of GBM according to WHO classification.
Management
Initial treatment involves surgical resection followed by chemoradiotherapy (CRT) and adjuvant TMZ.
Management of recurrence may include systemic therapy, reirradiation, or additional surgery.
Monitoring & Follow-up
Patients should be monitored for recurrence through imaging and clinical indicators.
Risks
High risk of recurrence and poor prognosis associated with GBM.
Patient & Prescribing Data
Adults with recurrent glioblastoma post initial treatment.
Treatment options include intensified TMZ, bevacizumab, irinotecan, and lomustine.
Clinical Best Practices
Utilize a multidisciplinary team for treatment planning and management.
Assess MGMT status and extent of surgical resection as critical prognostic indicators.
Consider patient eligibility for reirradiation based on clinical parameters.
by Jean-Baptiste Barbe-Richaud, Hélène Cebula, Julien Todeschi, Marie des Neiges Santin, Seyyid Baloglu, Roland Schott, Mathieu Cotton, Aurélien Blouet, Maxime Bobin, Georges Noël, Laura Somme
